AAP
BNTC icon

Arax Advisory Partners’s Benitec Biopharma BNTC Stock Holding History

Arax Advisory Partners’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24
Closed -$337 – 4127
2025
Q3 		$337 Buy
+24
New +$306 ﹤0.01% 3407

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Arax Advisory Partners's BNTC Position: Q4 2025 in Review

Arax Advisory Partners sold out of Benitec Biopharma (BNTC) in Q4 2025, closing a stake of 24 shares — an estimated $337 sold.

Arax Advisory Partners first reported a position in BNTC in Q3 2025 and held it in 1 quarter. The position peaked at $337 in Q3 2025. 72 funds tracked by Wall St. Rank hold BNTC as of Q4 2025.

  • Arax Advisory Partners reported no remaining Benitec Biopharma position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 24 Benitec Biopharma shares in Q4 2025, an estimated $337.
  • Arax Advisory Partners first reported a position in Benitec Biopharma in Q3 2025 and held it in 1 quarter.
  • Arax Advisory Partners's Benitec Biopharma position peaked at $337 in Q3 2025.
  • 72 funds tracked by Wall St. Rank held Benitec Biopharma as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.